Pharming Group Receives UK Approval for Joenja, Expanding Global Presence

Pharming Group (NASDAQ: PHAR) has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Joenja, a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). This marks the first approval specifically for APDS in the UK and expands Joenja’s global presence, following approvals in the United States and Israel.

The UK approval is a significant regulatory milestone for Pharming Group, and the company is actively working to comply with the European Medicines Agency’s (EMA) Committee for Medicinal Products (CHMP) requirements in the EU. The CHMP issued an outstanding issue list in May, with Pharming responding to these challenges within the given deadlines. The company expects to complete these tasks before the deadline of January 2026.

In addition to the UK approval, Joenja is currently under review in Canada and Australia. Although the deadline for regulatory approval in Canada has been extended beyond 2024, Pharming Group maintains a positive outlook for American Depositary Receipts (ADRs) traded in the US market.

HC Wainwright analysts have maintained their buy recommendation and price target on Pharming Group’s US-traded ADRs, reaffirming their confidence in the company’s prospects. Ongoing regulatory reviews in other countries indicate the potential for further expansion of Joenja’s market reach in the near future.

Pharming Group has reported significant growth in financial results and patient enrollment for its key products RUCONEST and Joenja. RUCONEST sales increased 23% in the second quarter, and Joenja also experienced significant sales growth. The company has completed enrollment for its first leniolisib study and is beginning a Phase 2 study. Full-year sales guidance remains between $280 million and $295 million, with second-quarter sales growth at 35% and gross margin stable at 89%.

Both RUCONEST and Joenja are showing strong sales growth and patient enrollment, although operating expenses have increased due to investments in Joenja and other areas. Pharming Group is optimistic about Joenja’s commercial potential in APDS and other indications.

Pharming Group’s ongoing regulatory efforts and expanding global presence position the company for continued growth and success in the biopharmaceutical industry.